Relinase

Haloperidol is a first-generation typical antipsychotic medication that primarily exerts its therapeutic effects by antagonizing dopamine D2 receptors in the brain, achieving maximum antipsychotic efficacy at approximately 72% receptor occupancy.[1] Developed as part of a research effort into potent analgesics at Janssen Pharmaceutica in Belgium, it was synthesized on February 11, 1958, by Paul Janssen and rapidly progressed to clinical trials due to its unexpected neuroleptic properties observed in animal models, where it induced catalepsy rather than analgesia.[2] Marketed under the brand name Haldol® starting in October 1959, haloperidol quickly became a cornerstone of psychiatric treatment for its efficacy in managing acute and chronic psychotic symptoms, marking a pivotal advancement in 20th-century biological psychiatry.[2]